ViroGates A/S
Copenhagen Stock Exchange VIRO.CO
ViroGates A/S Price to Earnings Ratio (P/E) on January 14, 2025: -8.33
-
ViroGates A/S 52-week high Price to Earnings Ratio (P/E) is -3.37 on April 18, 2024, which is 59.55% above the current Price to Earnings Ratio (P/E).
-
ViroGates A/S 52-week low Price to Earnings Ratio (P/E) is -13.53 on November 12, 2024, which is -62.51% below the current Price to Earnings Ratio (P/E).
-
ViroGates A/S average Price to Earnings Ratio (P/E) for the last 52 weeks is -5.01.
| Date | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield |
|---|
| CEO | Mr. Jakob Knudsen |
| IPO Date | June 26, 2018 |
| Location | Denmark |
| Headquarters | BanevAenget 13 |
| Employees | 10 |
| Sector | Health Care |
| Industries | |
ViroGates A/S develops and markets prognostic products for the healthcare sector. It offers suPARnostic, a blood test that measures the soluble urokinase plasminogen activator receptor (suPAR) protein in the bloodstream used for emergency departments in hospitals to improve clinical decisions on hospitalization or discharge of acute medical patients and reduce healthcare cost. The company also provides suPARnostic TurbiLatex, a latex particle-enhanced turbidimetric immunoassay that quantitatively determines the suPAR level in human K2-EDTA- or lithium heparin plasma samples; suPARnostic Quick Triage kit, which is used in the point of care situation for early warning and patient triaging; and suPARnostic ELISA that provides fully quantitative results. Its suPAR prognostic tool used in various diseases, such as cardiovascular, kidney, cancer, diabetes, liver, infectious, respiratory, and rheumatic. The company was incorporated in 2000 and is headquartered in Birkerød, Denmark.
Past 5 years
USD 0.20
USD 24.73
USD 70.50
StockViz Staff
January 15, 2025
Any question? Send us an email